CD8A and breast cancer: For example, the in situ DCs‐primed vaccine (HELA‐Exos), loaded with ICD inducers, ELANE and Hiltonol, has been confirmed in in vivo studies to enhance the immune response against BC by stimulating cDC1s, thereby increasing CD8+ T cell‐mediated immunity.74